Chicago Trust’s Myriad Genetics MYGN Stock Holding History

Chicago Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,500	Closed	-$207K	–	346
2021 Q4	$207K	Hold	7,500	–	–	0.04%	327
2021 Q3	$242K	Sell	7,500 -2,000	-21%	-$66.4K	0.05%	291
2021 Q2	$291K	Hold	9,500	–	–	0.07%	249
2021 Q1	$289K	Buy	+9,500	New	+$270K	0.1%	168
2020 Q1	–	Sell	-9,500	Closed	-$259K	–	178
2019 Q4	$259K	Hold	9,500	–	–	0.11%	155
2019 Q3	$272K	Buy	9,500 +2,000	+27%	+$58.3K	0.11%	154
2019 Q2	$208	Hold	7,500	–	–	0.09%	178
2019 Q1	$249	Hold	7,500	–	–	0.11%	164
2018 Q4	$218	Buy	7,500 +2,500	+50%	+$89.9K	0.1%	150
2018 Q3	$230K	Buy	+5,000	New	+$222K	0.09%	155
2016 Q1	–	Sell	-5,000	Closed	-$216K	–	160
2015 Q4	$216K	Buy	+5,000	New	+$211K	0.08%	145

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Chicago Trust's MYGN Position: Q1 2022 in Review

Chicago Trust sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 7,500 shares — an estimated $207K sold.

Chicago Trust first reported a position in MYGN in Q4 2015 and held it in 11 quarters. The position peaked at $291K in Q2 2021. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

Chicago Trust reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
Chicago Trust sold 7,500 Myriad Genetics shares in Q1 2022, an estimated $207K.
Chicago Trust first reported a position in Myriad Genetics in Q4 2015 and held it in 11 quarters.
Chicago Trust's Myriad Genetics position peaked at $291K in Q2 2021.
205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Chicago Trust's 13F filing for Q1 2022, filed 12 Apr 2022.